Opportunistic Infections Project Team of the, Collaboration of Ob; Mocroft, Amanda; Reiss, Peter; Kirk, Ole; Mussini, Cristina; Girardi, Enrico; Morlat, Philippe; Stephan, Christoph; De Wit, Stephane; Doerholt, Katja; Ghosn, Jade; Bucher, Heiner C; Lundgren, Jens D; Chene, Genevieve; Miro, Jose M; Furrer, Hansjakob (2010). Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL? Clinical infectious diseases, 51(5), pp. 611-9. Cary, N.C.: Oxford University Press 10.1086/655761
|
Text
51-5-611.pdf - Published Version Available under License Publisher holds Copyright. Download (445kB) | Preview |
Current guidelines suggest that primary prophylaxis for Pneumocystis jiroveci pneumonia (PcP) can be safely stopped in human immunodeficiency virus (HIV)-infected patients who are receiving combined antiretroviral therapy (cART) and who have a CD4 cell count >200 cells/microL. There are few data regarding the incidence of PcP or safety of stopping prophylaxis in virologically suppressed patients with CD4 cell counts of 101-200 cells/microL.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology |
UniBE Contributor: |
Furrer, Hansjakob |
ISSN: |
1058-4838 |
Publisher: |
Oxford University Press |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:12 |
Last Modified: |
05 Dec 2022 14:02 |
Publisher DOI: |
10.1086/655761 |
PubMed ID: |
20645862 |
Web of Science ID: |
000280623900021 |
BORIS DOI: |
10.48350/2702 |
URI: |
https://boris.unibe.ch/id/eprint/2702 (FactScience: 205569) |
Actions (login required)
 |
Edit item |